The DOI matches its Crossref record; 248 of the 248 references it cites were found in a registry or an index.
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Open accessAbstract
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular processes, including the regulation of transcription, apoptosis and the DNA damage response. PARP1 possesses Poly (ADP-ribose) activity and when activated by DNA damage, adds branched PAR chains to facilitate the recruitment of other repair proteins to promote the repair of DNA single-strand breaks. PARP inhibitors (PARPi) were the first approved cancer drugs that specifically targeted the DNA damage response in BRCA1/2 mutated breast and ovarian cancers. Since then, there has been significant advances in our understanding of the mechanisms behind sensitization of tumors to PARP inhibitors and expansion of the use of PARPi to treat several other cancer types. Here, we review the recent advances in the proposed mechanisms of action of PARPi, biomarkers of the tumor response to PARPi, clinical advances in PARPi therapy, including the potential of combination therapies and mechanisms of tumor resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K.-A., Mooij, T. M., Roos-Blom, M.-J., Jervis, S., van Leeuwen, F. E., Milne, R. L., Andrieu, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7112 · Cited by 2,954
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
DNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
MicroRNA: Biogenesis, Function and Role in Cancer
MacFarlane, L.-A., & R. Murphy, P. (2010) · Current Genomics · doi:10.2174/138920210793175895 · Cited by 1,584
Saam, J., Arnell, C., Theisen, A., Moyes, K., Marino, I., Roundy, K. M., & Wenstrup, R. J. (2015) · Oncology · doi:10.1159/000437307 · Cited by 1,526
The DNA methyltransferase family: a versatile toolkit for epigenetic regulation
Lyko, F. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.80 · Cited by 1,467
The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
Li, T., & Chen, Z. J. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180139 · Cited by 1,293
Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., Winer, E. P., Tung, N. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2477 · Cited by 1,136
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,056
Sgs1 Helicase and Two Nucleases Dna2 and Exo1 Resect DNA Double-Strand Break Ends
Zhu, Z., Chung, W.-H., Shim, E. Y., Lee, S. E., & Ira, G. (2008) · Cell · doi:10.1016/j.cell.2008.08.037 · Cited by 1,051
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Bouwman, P., Aly, A., Escandell, J. M., Pieterse, M., Bartkova, J., van der Gulden, H., Hiddingh, S., Thanasoula, M., Kulkarni, A., Yang, Q., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1831 · Cited by 1,001
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Replication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1909707 · Cited by 913
Temozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Krishnakumar, R., & Kraus, W. L. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.017 · Cited by 836
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Wang, M., Wu, W., Wu, W., Rosidi, B., Zhang, L., Wang, H., & Iliakis, G. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl840 · Cited by 820
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
Pattern Recognition Receptors and the Host Cell Death Molecular Machinery
Amarante-Mendes, G. P., Adjemian, S., Branco, L. M., Zanetti, L. C., Weinlich, R., & Bortoluci, K. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02379 · Cited by 749
Pantelidou, C., Sonzogni, O., De Oliveria Taveira, M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1218 · Cited by 743
DNA methylation, methyltransferases, and cancer
Robertson, K. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204341 · Cited by 736
Purified human BRCA2 stimulates RAD51-mediated recombination
Jensen, R. B., Carreira, A., & Kowalczykowski, S. C. (2010) · Nature · doi:10.1038/nature09399 · Cited by 715
Mao, Z., Bozzella, M., Seluanov, A., & Gorbunova, V. (2008) · Cell Cycle · doi:10.4161/cc.7.18.6679 · Cited by 691
Chambon, P., Weill, J. D., & Mandel, P. (1963) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(63)90024-x · Cited by 654
Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R., Syndikus, I., Ralph, C., Jain, S., Varughese, M., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30684-9 · Cited by 634
Menissier de Murcia, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 627
PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites
Haince, J.-F., McDonald, D., Rodrigue, A., Déry, U., Masson, J.-Y., Hendzel, M. J., & Poirier, G. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m706734200 · Cited by 608
PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination
Bryant, H. E., Petermann, E., Schultz, N., Jemth, A., Loseva, O., Issaeva, N., Johansson, F., Fernandez, S., McGlynn, P., & Helleday, T. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.206 · Cited by 602
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Xu, G., Chapman, J. R., Brandsma, I., Yuan, J., Mistrik, M., Bouwman, P., Bartkova, J., Gogola, E., Warmerdam, D., Barazas, M., et al. (2015) · Nature · doi:10.1038/nature14328 · Cited by 593
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562
CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle
Yun, M. H., & Hiom, K. (2009) · Nature · doi:10.1038/nature07955 · Cited by 556
Epidemiology of prostate cancer
Crawford, E. D. (2003) · Urology · doi:10.1016/j.urology.2003.10.013 · Cited by 543
Patel, A. G., Sarkaria, J. N., & Kaufmann, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013715108 · Cited by 541
Pearce, A., Haas, M., Viney, R., Pearson, S.-A., Haywood, P., Brown, C., & Ward, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0184360 · Cited by 534
Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30029-4 · Cited by 533
Novel inhibitors of poly(ADP-ribose) synthetase
Purnell, M. R., & Whish, W. J. (1980) · Biochemical Journal · doi:10.1042/bj1850775 · Cited by 527
High speed of fork progression induces DNA replication stress and genomic instability
Maya-Mendoza, A., Moudry, P., Merchut-Maya, J. M., Lee, M., Strauss, R., & Bartek, J. (2018) · Nature · doi:10.1038/s41586-018-0261-5 · Cited by 514 · cited 1×
“This suggests an underlying mechanism of PARPi toxicity could be the result of DSBs occurring as a result of high-speed replication (Maya-Mendoza et al., 2018; Quinet and Vindigni, 2018).”
BackgroundMandelker, D., Zhang, L., Kemel, Y., Stadler, Z. K., Joseph, V., Zehir, A., Pradhan, N., Arnold, A., Walsh, M. F., Li, Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.11137 · Cited by 511
Base Excision Repair Is Impaired in Mammalian Cells Lacking Poly(ADP-ribose) Polymerase-1
Dantzer, F., de la Rubia, G., Ménissier-de Murcia, J., Hostomsky, Z., de Murcia, G., & Schreiber, V. (2000) · Biochemistry · doi:10.1021/bi0003442 · Cited by 505
Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479
Epidemiology of lung cancer in China
Cao, M., & Chen, W. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.12916 · Cited by 471
Gupta, R., Somyajit, K., Narita, T., Maskey, E., Stanlie, A., Kremer, M., Typas, D., Lammers, M., Mailand, N., Nussenzweig, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.050 · Cited by 469
Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types
Heeke, A. L., Pishvaian, M. J., Lynce, F., Xiu, J., Brody, J. R., Chen, W.-J., Baker, T. M., Marshall, J. L., & Isaacs, C. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00286 · Cited by 467
DNA double strand break repair via non-homologous end-joining.
Davis, A. J., & Chen, D. J. (2013) · PubMed · doi:10.3978/j.issn.2218-676x.2013.04.02 · Cited by 456
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Noordermeer, S. M., & van Attikum, H. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.008 · Cited by 456
Lin, K. K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L.-T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0715 · Cited by 432
Epidemiology of lung cancer in China
Chen, W., Zheng, R., Zeng, H., & Zhang, S. (2015) · Thoracic Cancer · doi:10.1111/1759-7714.12169 · Cited by 428
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Dev, H., Chiang, T.-W. W., Lescale, C., de Krijger, I., Martin, A. G., Pilger, D., Coates, J., Sczaniecka-Clift, M., Wei, W., Ostermaier, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0140-1 · Cited by 417
Targeting WEE1 Kinase in Cancer
Matheson, C. J., Backos, D. S., & Reigan, P. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.006 · Cited by 408
Kondrashova, O., Nguyen, M., Shield-Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G.-Y., Barker, H., Jasin, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0419 · Cited by 407
Tumour lineage shapes BRCA-mediated phenotypes
Jonsson, P., Bandlamudi, C., Cheng, M. L., Srinivasan, P., Chavan, S. S., Friedman, N. D., Rosen, E. Y., Richards, A. L., Bouvier, N., Selcuklu, S. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1382-1 · Cited by 401
Taglialatela, A., Alvarez, S., Leuzzi, G., Sannino, V., Ranjha, L., Huang, J.-W., Madubata, C., Anand, R., Levy, B., Rabadan, R., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.036 · Cited by 394
Hanzlikova, H., Kalasova, I., Demin, A. A., Pennicott, L. E., Cihlarova, Z., & Caldecott, K. W. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.004 · Cited by 393
de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1250 · Cited by 387
Yamamoto, J. F., & Goodman, M. T. (2008) · Cancer Causes & Control · doi:10.1007/s10552-007-9097-2 · Cited by 383
Gogola, E., Duarte, A. A., de Ruiter, J. R., Wiegant, W. W., Schmid, J. A., de Bruijn, R., James, D. I., Guerrero Llobet, S., Vis, D. J., Annunziato, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.008 · Cited by 374
Hall, M. J., Reid, J. E., Burbidge, L. A., Pruss, D., Deffenbaugh, A. M., Frye, C., Wenstrup, R. J., Ward, B. E., Scholl, T. A., & Noll, W. W. (2009) · Cancer · doi:10.1002/cncr.24200 · Cited by 365
Vaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
Serine ADP-ribosylation depends on HPF1
Bonfiglio, J. J., Fontana, P., Zhang, Q., Colby, T., Gibbs-Seymour, I., Atanassov, I., Bartlett, E., Zaja, R., Ahel, I., & Matic, I. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.01.003 · Cited by 352
Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
Ying, S., Hamdy, F. C., & Helleday, T. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3417 · Cited by 346
Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency
Cong, K., Peng, M., Kousholt, A. N., Lee, W. T. C., Lee, S., Nayak, S., Krais, J., VanderVere-Carozza, P. S., Pawelczak, K. S., Calvo, J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.06.011 · Cited by 345
On the formation of a novel adenylic compound by enzymatic extracts of liver nuclei
Chambon, P., Weill, J. D., Doly, J., Strosser, M. T., & Mandel, P. (1966) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(66)90502-x · Cited by 344
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181d38f2f · Cited by 339
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123319 · Cited by 332
Rondinelli, B., Gogola, E., Yücel, H., Duarte, A. A., van de Ven, M., van der Sluijs, R., Konstantinopoulos, P. A., Jonkers, J., Ceccaldi, R., Rottenberg, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3626 · Cited by 332
Fok, J. H. L., Ramos-Montoya, A., Vazquez-Chantada, M., Wijnhoven, P. W. G., Follia, V., James, N., Farrington, P. M., Karmokar, A., Willis, S. E., Cairns, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12836-9 · Cited by 331
Involvement of poly(ADP-ribose) polymerase in base excision repair
Dantzer, F., Schreiber, V., Niedergang, C., Trucco, C., Flatter, E., Rubia, G. D. L., Oliver, J., Rolli, V., Ménissier-de Murcia, J., & de Murcia, G. (1999) · Biochimie · doi:10.1016/s0300-9084(99)80040-6 · Cited by 327
PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
Rulten, S. L., Fisher, A. E. O., Robert, I., Zuma, M. C., Rouleau, M., Ju, L., Poirier, G., Reina-San-Martin, B., & Caldecott, K. W. (2011) · Molecular Cell · doi:10.1016/j.molcel.2010.12.006 · Cited by 326
Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., Ji, J., Monks, A., Low, J. A., Chen, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.7681 · Cited by 326
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R., Rayter, S., Tutt, A. N., & Ashworth, A. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.61 · Cited by 322
Fisher, A. E. O., Hochegger, H., Takeda, S., & Caldecott, K. W. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02248-06 · Cited by 314
HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity
Gibbs-Seymour, I., Fontana, P., Rack, J. G. M., & Ahel, I. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.03.008 · Cited by 309
Studies on the Polymer of Adenosine Diphosphate Ribose
Nishizuka, Y., Ueda, K., Nakazawa, K., & Hayaishi, O. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)95947-8 · Cited by 308
Pathway choice in DNA double strand break repair: observations of a balancing act
Brandsma, I., & Gent, D. C. (2012) · Genome Integrity · doi:10.1186/2041-9414-3-9 · Cited by 308
The cellular response to general and programmed DNA double strand breaks
Bassing, C. H., & Alt, F. W. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.06.001 · Cited by 303
Strom, C. E., Johansson, F., Uhlen, M., Szigyarto, C. A.-K., Erixon, K., & Helleday, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1241 · Cited by 296
Kondrashova, O., Topp, M., Nesic, K., Lieschke, E., Ho, G.-Y., Harrell, M. I., Zapparoli, G. V., Hadley, A., Holian, R., Boehm, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05564-z · Cited by 296
Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 293
PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
Brenner, J. C., Feng, F. Y., Han, S., Patel, S., Goyal, S. V., Bou-Maroun, L. M., Liu, M., Lonigro, R., Prensner, J. R., Tomlins, S. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3648 · Cited by 290
Oza, A. M., Tinker, A. V., Oaknin, A., Shapira-Frommer, R., McNeish, I. A., Swisher, E. M., Ray-Coquard, I., Bell-McGuinn, K., Coleman, R. L., O'Malley, D. M., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.022 · Cited by 281
Boehler, C., Gauthier, L. R., Mortusewicz, O., Biard, D. S., Saliou, J.-M., Bresson, A., Sanglier-Cianferani, S., Smith, S., Schreiber, V., Boussin, F., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016574108 · Cited by 277
RPA Coordinates DNA End Resection and Prevents Formation of DNA Hairpins
Chen, H., Lisby, M., & Symington, L. S. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.04.032 · Cited by 276
Hopkins, T. A., Shi, Y., Rodriguez, L. E., Solomon, L. R., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Wilsbacher, J. L., Gao, W., Olson, A. M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0191-t · Cited by 270
The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks
Ali, A. A. E., Timinszky, G., Arribas-Bosacoma, R., Kozlowski, M., Hassa, P. O., Hassler, M., Ladurner, A. G., Pearl, L. H., & Oliver, A. W. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2335 · Cited by 268
Langelier, M.-F., Riccio, A. A., & Pascal, J. M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku474 · Cited by 265
Kim, D.-S., Camacho, C. V., Nagari, A., Malladi, V. S., Challa, S., & Kraus, W. L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.06.020 · Cited by 260
A systematic review of the international prevalence of BRCA mutation in breast cancer
Armstrong, N., Ryder, S., Forbes, C., Ross, J., & Quek, R. G. (2019) · Clinical Epidemiology · doi:10.2147/clep.s206949 · Cited by 259
Cyclic GMP–AMP as an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA
Kato, K., Omura, H., Ishitani, R., & Nureki, O. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044813 · Cited by 255
PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1
Pines, A., Vrouwe, M. G., Marteijn, J. A., Typas, D., Luijsterburg, M. S., Cansoy, M., Hensbergen, P., Deelder, A., de Groot, A., Matsumoto, S., et al. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201112132 · Cited by 254
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
T. H. B. C. S. G., Iqbal, J., Ragone, A., Lubinski, J., Lynch, H. T., Moller, P., Ghadirian, P., Foulkes, W. D., Armel, S., Eisen, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.483 · Cited by 252
BRCA1 and BRCA2 mutations and treatment strategies for breast cancer
Godet, I., & M. Gilkes, D. (2017) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000228 · Cited by 250
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Hopkins, T. A., Ainsworth, W. B., Ellis, P. A., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Abraham, V. C., Algire, M. A., Shi, Y., Olson, A. M., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0138 · Cited by 250
Serine is a new target residue for endogenous ADP-ribosylation on histones
Leidecker, O., Bonfiglio, J. J., Colby, T., Zhang, Q., Atanassov, I., Zaja, R., Palazzo, L., Stockum, A., Ahel, I., & Matic, I. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2180 · Cited by 243
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Farago, A. F., Yeap, B. Y., Stanzione, M., Hung, Y. P., Heist, R. S., Marcoux, J. P., Zhong, J., Rangachari, D., Barbie, D. A., Phat, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0582 · Cited by 238
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Hodgson, D. R., Dougherty, B. A., Lai, Z., Fielding, A., Grinsted, L., Spencer, S., O’Connor, M. J., Ho, T. W., Robertson, J. D., Lanchbury, J. S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0274-8 · Cited by 233
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Fang, Y., McGrail, D. J., Sun, C., Labrie, M., Chen, X., Zhang, D., Ju, Z., Vellano, C. P., Lu, Y., Li, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.001 · Cited by 233
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination–Defective Cells
Gottipati, P., Vischioni, B., Schultz, N., Solomons, J., Bryant, H. E., Djureinovic, T., Issaeva, N., Sleeth, K., Sharma, R. A., & Helleday, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4716 · Cited by 227
PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
Das, B. B., Huang, S.-Y. N., Murai, J., Rehman, I., Amé, J.-C., Sengupta, S., Das, S. K., Majumdar, P., Zhang, H., Biard, D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku088 · Cited by 225
Dungey, F. A., Löser, D. A., & Chalmers, A. J. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.07.031 · Cited by 220
PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
Sugimura, K., Takebayashi, S.-I., Taguchi, H., Takeda, S., & Okumura, K. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200806068 · Cited by 211
PARP inhibitors in ovarian cancer
Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Di Napoli, M., De Vita, F., Pignata, S., Ciardiello, F., & Orditura, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.002 · Cited by 211
Miwa, M., Tanaka, M., Matsushima, T., & Sugimura, T. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42597-0 · Cited by 209
Triple-Negative Breast Cancer and the Potential for Targeted Therapy
Jhan, J.-R., & Andrechek, E. R. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0117 · Cited by 205
Muvarak, N. E., Chowdhury, K., Xia, L., Robert, C., Choi, E. Y., Cai, Y., Bellani, M., Zou, Y., Singh, Z. N., Duong, V. H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.002 · Cited by 201
Christie, E. L., Fereday, S., Doig, K., Pattnaik, S., Dawson, S.-J., & Bowtell, D. D. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4627 · Cited by 196
Hanzlikova, H., Gittens, W., Krejcikova, K., Zeng, Z., & Caldecott, K. W. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1246 · Cited by 192
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
Reisländer, T., Lombardi, E. P., Groelly, F. J., Miar, A., Porru, M., Di Vito, S., Wright, B., Lockstone, H., Biroccio, A., Harris, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11048-5 · Cited by 192
Liao, H., Ji, F., Helleday, T., & Ying, S. (2018) · EMBO reports · doi:10.15252/embr.201846263 · Cited by 187
Transcriptional Roles of PARP1 in Cancer
Schiewer, M. J., & Knudsen, K. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0672 · Cited by 186
Godon, C., Cordelieres, F. P., Biard, D., Giocanti, N., Megnin-Chanet, F., Hall, J., & Favaudon, V. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn403 · Cited by 186
Friedlander, M., Matulonis, U., Gourley, C., du Bois, A., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0271-y · Cited by 185
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
Sishc, B., & Davis, A. (2017) · Cancers · doi:10.3390/cancers9070081 · Cited by 181
Plummer, R., Lorigan, P., Steven, N., Scott, L., Middleton, M. R., Wilson, R. H., Mulligan, E., Curtin, N., Wang, D., Dewji, R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2113-1 · Cited by 179
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
Jiang, X., Li, X., Li, W., Bai, H., & Zhang, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14133 · Cited by 177
Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule
Zhao, Q., Lan, T., Su, S., & Rao, Y. (2019) · Chemical Communications · doi:10.1039/c8cc07813k · Cited by 176
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S., Lin, K. K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 174
Hu, Y., Petit, S. A., Ficarro, S. B., Toomire, K. J., Xie, A., Lim, E., Cao, S. A., Park, E., Eck, M. J., Scully, R., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0891 · Cited by 167
Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Esposito, M. T., Zhao, L., Fung, T. K., Rane, J. K., Wilson, A., Martin, N., Gil, J., Leung, A. Y., Ashworth, A., & Eric So, C. W. (2015) · Nature Medicine · doi:10.1038/nm.3993 · Cited by 167
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy
Xu, Y., & Her, C. (2015) · Biomolecules · doi:10.3390/biom5031652 · Cited by 164
The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers
Cavanagh, H., & Rogers, K. (2015) · Hereditary Cancer in Clinical Practice · doi:10.1186/s13053-015-0038-x · Cited by 163
Ma, C. J., Gibb, B., Kwon, Y., Sung, P., & Greene, E. C. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1125 · Cited by 162
TRIP13 regulates DNA repair pathway choice through REV7 conformational change
Clairmont, C. S., Sarangi, P., Ponnienselvan, K., Galli, L. D., Csete, I., Moreau, L. A., Adelmant, G., Chowdhury, D., Marto, J. A., & D’Andrea, A. D. (2020) · Nature Cell Biology · doi:10.1038/s41556-019-0442-y · Cited by 161
Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers
de Almeida, B. P., Apolónio, J. D., Binnie, A., & Castelo‐Branco, P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5403-0 · Cited by 159
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.191 · Cited by 158
Holliday junction resolution: Regulation in space and time
Matos, J., & West, S. C. (2014) · DNA Repair · doi:10.1016/j.dnarep.2014.03.013 · Cited by 158
Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
Karnak, D. M., Engelke, C. G., Parsels, L. A., Kausar, T., Wei, D., Robertson, J. R., Marsh, K. B., Davis, M. A., Zhao, L., Maybaum, J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1038 · Cited by 158
Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors
Skalitzky, D. J., Marakovits, J. T., Maegley, K. A., Ekker, A., Yu, X., Hostomský, Z., Webber, S. E., Eastman, B. W., Almassy, R. J., Li, J., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255769 · Cited by 152
Oh, M., Alkhushaym, N., Fallatah, S., Althagafi, A. A., Aljadeed, R., Alsowaida, Y. S., Jeter, J., Martin, J. R., Babiker, H. M., McBride, A., et al. (2019) · The Prostate · doi:10.1002/pros.23795 · Cited by 151
Choi, Y. E., Meghani, K. A., Brault, M. E., Leclerc, L., He, Y. J., Day, T. A., Elias, K. M., Drapkin, R., Weinstock, D. M., Dao, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.046 · Cited by 149
BRCA1/BRCA2Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
Lee, A., Moon, B.-I., & Kim, T. H. (2019) · Annals of Laboratory Medicine · doi:10.3343/alm.2020.40.2.114 · Cited by 148
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Min, A., Im, S., Yoon, Y., Song, S., Nam, H.-J., Hur, H.-S., Kim, H., Lee, K.-H., Han, S., Oh, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0950 · Cited by 146
Fujimura, S., Hasegawa, S., Shimizu, Y., & Sügimura, T. (1967) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(67)90043-3 · Cited by 145
DAMPs, ageing, and cancer: The ‘DAMP Hypothesis’
Huang, J., Xie, Y., Sun, X., Zeh, H. J., Kang, R., Lotze, M. T., & Tang, D. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2014.10.004 · Cited by 144
Ettl, J., Quek, R. G. W., Lee, K. H., Rugo, H. S., Hurvitz, S. A., Gonçalvès, A., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martín, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy257 · Cited by 143
Base excision repair is efficient in cells lacking poly(ADP-ribose) polymerase 1
Vodenicharov, M. D., Sallmann, F. R., Satoh, M. S., & Poirier, G. G. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.20.3887 · Cited by 142
Maede, Y., Shimizu, H., Fukushima, T., Kogame, T., Nakamura, T., Miki, T., Takeda, S., Pommier, Y. G., & Murai, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0551 · Cited by 142
Koch, S. S. C., Thoresen, L. H., Tikhe, J. G., Maegley, K. A., Almassy, R. J., Li, J., Yu, X., Zook, S. E., Kumpf, R. A., Zhang, C., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020259n · Cited by 141
Specific inhibition of poly adpribose polymerase by thymidine and nicotinamide in HeLa cells
Preiss, J., SCHLAEGER, R., & Hilz, H. (1971) · FEBS Letters · doi:10.1016/0014-5793(71)80524-0 · Cited by 139
The kinase polypharmacology landscape of clinical PARP inhibitors
Antolín, A. A., Ameratunga, M., Banerji, U., Clarke, P. A., Workman, P., & Al‐Lazikani, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-59074-4 · Cited by 138
Survival and prognostic factors in BRCA1-associated breast cancer
Brekelmans, C. T. M., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H. T., Tilanus‐Linthorst, M. M. A., Bartels, C. C. M., Kriege, M., van Geel, A. N., Crépin, C., Blom, J., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj095 · Cited by 137
Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death
Houl, J. H., Ye, Z., Brosey, C. A., Balapiti-Modarage, L. P. F., Namjoshi, S., Bacolla, A., Laverty, D. J., Walker, B. L., Pourfarjam, Y., Warden, L. S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13508-4 · Cited by 136
Poly(ADP-ribose) Reactivates Stalled DNA Topoisomerase I and Induces DNA Strand Break Resealing
Malanga, M., & Althaus, F. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300437200 · Cited by 135
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
Geenen, J. J. J., Linn, S. C., Beijnen, J. H., & Schellens, J. H. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0587-4 · Cited by 135
Parsels, L. A., Karnak, D. M., Parsels, J. D., Zhang, Q., Vélez-Padilla, J., Reichert, Z. R., Wahl, D. R., Maybaum, J., O’Connor, M. J., Lawrence, T. S., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0455 · Cited by 135
The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency
Gatti, M., Imhof, R., Huang, Q. D., Baudis, M., & Altmeyer, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107985 · Cited by 135
Min, W., Bruhn, C., Grigaravičius, P., Zhou, Z., Li, F., Krüger, A., Siddeek, B., Greulich, K., Popp, O., Meisezahl, C., et al. (2013) · Nature Communications · doi:10.1038/ncomms3993 · Cited by 129
Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications
Yang, X., Wong, M. P. M., & Ng, R. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184576 · Cited by 129
Beck, C., Boehler, C., Guirouilh‐Barbat, J., Bonnet, M.-E., Illuzzi, G., Rondé, P., Gauthier, L., Magroun, N., Rajendran, A., López, B. S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku174 · Cited by 128
The p65 subunit of NF-κB and PARP1 assist Snail1 in activating fibronectin transcription
Stanisavljević, J., Porta-de-la-Riva, M., Batlle, R., de Herreros, A. G., & Baulida, J. (2011) · Journal of Cell Science · doi:10.1242/jcs.078824 · Cited by 127
Pulliam, N., Fang, F., Özeş, A., Tang, J., Adewuyi, A., Keer, H. N., Lyons, J. F., Baylin, S. B., Matei, D. E., Nakshatri, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0204 · Cited by 126
Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
Brunner, M., Wu, Z., Krautz, C., Pilarsky, C. P., Grützmann, R., & Weber, G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184543 · Cited by 122
YAMAGUCHI, H., Du, Y., Nakai, K., Ding, M., Chang, S. H., Hsu, J. L., Yao, J., Wei, Y., Nie, L., Jiao, S., et al. (2017) · Oncogene · doi:10.1038/onc.2017.311 · Cited by 121
Michelena, J., Lezaja, A., Teloni, F., Schmid, T., Imhof, R., & Altmeyer, M. (2018) · Nature Communications · doi:10.1038/s41467-018-05031-9 · Cited by 121
Polymerization of the adenosine 5′-diphosphate ribose moiety of NAD by rat liver nuclear enzyme
Sügimura, T., Fujimura, S., Hasegawa, S., & Kawamura, Y. (1967) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(67)90507-2 · Cited by 120
Tuli, R., Shiao, S. L., Nissen, N. N., Tighiouart, M., Kim, S., Osipov, A., Bryant, M., Ristow, L., Placencio-Hickok, V., Hoffman, D., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.060 · Cited by 120
Friedlander, M. L., Meniawy, T. M., Markman, B., Mileshkin, L., Harnett, P. R., Millward, M., Lundy, J., Freimund, A. E., Norris, C., Mu, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30396-1 · Cited by 117
BRCA Mutations and Breast Cancer Prevention
Kotsopoulos, J. (2018) · Cancers · doi:10.3390/cancers10120524 · Cited by 116
The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases
Solier, S., & Pommier, Y. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1555-2 · Cited by 114
Montavon, C., Gloss, B., Warton, K., Barton, C. A., Statham, A. L., Scurry, J., Tabor, B., Nguyen, T. V., Qu, W., Samimi, G., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.11.026 · Cited by 113
Schoonen, P. M., Talens, F., Stok, C., Gogola, E., Heijink, A. M., Bouwman, P., Foijer, F., Tarsounas, M., Blatter, S., Jonkers, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15981 · Cited by 108
Wang, L., Yang, C., Xie, C., Jiang, J., Gao, M., Li, F., Li, Y., Bao, X., Fu, H., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.13947 · Cited by 108
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
Issaeva, N., Thomas, H. D., Djurenovic, T., Jaspers, J. E., Stoimenov, I., Kyle, S., Pedley, N., Gottipati, P., Zur, R., Sleeth, K. M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3416 · Cited by 106
Wang, D., Li, C., Zhang, Y., Wang, M., Jiang, N., Lin, X., Li, T., Roberts, T. M., Zhao, J. J., Cheng, H.-L. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.092 · Cited by 105
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
Francica, P., & Rottenberg, S. (2018) · Genome Medicine · doi:10.1186/s13073-018-0612-8 · Cited by 105
Studies on the Polymer of Adenosine Diphosphate Ribose
Reeder, R. H., Ueda, K., Honjo, T., Nishizuka, Y., & Hayaishi, O. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)95948-x · Cited by 104
XRCC1 interactions with base excision repair DNA intermediates
Nazarkina, Z. K., Khodyreva, S. N., Marsin, S., et al. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.10.002 · Cited by 99
Chabot, P., Hsia, T., Ryu, J., Горбунова, В. А., Belda-Iniesta, C., Ball, D., Kio, E. A., Mehta, M. P., Papp, K., Qin, Q., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2275-x · Cited by 98
Baxter, P. A., Su, J. M. F., Onar‐Thomas, A., Billups, C. A., Li, X., Poussaint, T. Y., Smith, E. R., Thompson, P., Adesina, A. M., Ansell, P. J., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa016 · Cited by 98
Vulnerabilities of PTEN – TP53 -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition
González‐Billalabeitia, E., Seitzer, N., Song, S. J., Song, M. S., Patnaik, A., Liu, X., Epping, M. T., Papa, A., Hobbs, R. M., Chen, M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0230 · Cited by 96
Allinson, S. L., Dianova, I. I., & Dianov, G. L. (2003) · Acta Biochimica Polonica · doi:10.18388/abp.2003_3724 · Cited by 94
Liu, L., Kong, M., Gassman, N. R., Freudenthal, B., Prasad, R., Zhen, S., Watkins, S. C., Wilson, S. H., & Houten, B. V. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1047 · Cited by 94
Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
Koppensteiner, R., Samartzis, E. P., Noske, A., von Teichman, A., Dedes, I., Gwerder, M., Imesch, P., Ikenberg, K., Moch, H., Fink, D. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100041 · Cited by 90
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
Laird, J. H., Lok, B. H., Ma, J., Bell, A., de Stanchina, E., Poirier, J. T., & Rudin, C. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0401 · Cited by 85
Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
Horton, J. K., Stefanick, D. F., Prasad, R., Gassman, N. R., Kedar, P. S., & Wilson, S. H. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0502 · Cited by 83
Cited by
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Advances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H.-G., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 312
Saturation genome editing maps the functional spectrum of pathogenic VHL alleles
Buckley, M., Terwagne, C., Ganner, A., Cubitt, L., Brewer, R., Kim, D.-K., Kajba, C. M., Forrester, N., Dace, P., De Jonghe, J., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01800-z · Cited by 62
Metadata
- Authors
- Rose, M., Burgess, J. T., O’Byrne, K., Richard, D. J., & Bolderson, E.
- Venue
- Frontiers in Cell and Developmental Biology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-09
- Volume
- 8
- Pages
- 564601-564601
- ISSN
- 2296-634X (ISSN-L)
- OpenAlex
- W3084114043
- Cited by
- 719
- References
- 248
- FWCI
- 26.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.